Shenzhen Hongxin Biotechnology
RNA drug research and development for cancer.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | CNY20.0m | Seed | |
| Total Funding | 000k | ||
Shenzhen Hongxin Biotechnology Co., Ltd., also known as MagicRNA, is a biotechnology company established in 2021 and based in Shenzhen, China. The company focuses on the research and development of RNA drugs, particularly for treating cancer and gynecological diseases.
The founder, Dr. Zha Gaofeng, is an expert for the "100 Talents Program" of Sun Yat-sen University and a postdoctoral fellow of the Karolinska Institutet. His multidisciplinary research background spans chemistry, materials, biology, and immunity, with a specialization in mRNA delivery. He has published over 20 SCI papers and collaborated with Prof. K. B. Sharpless, a Nobel Prize winner in Chemistry.
MagicRNA operates on a business model centered around its proprietary technology platforms. These include an mRNA sequence design platform, an mRNA synthesis platform, and a lipid nanoparticle (LNP) delivery platform. A key asset is the Engineered Cell Targeted LNPs (EnC-LNPs) platform, designed to deliver nucleic acid drugs to specific cells within the immune system, central nervous system, and tumors. The company also offers custom mRNA synthesis and LNP wrapping services. Its product pipeline includes infectious disease mRNA vaccines, mRNA tumor vaccines, and protein replacement therapies. The company's first tumor therapeutic drug, HN2201, has completed preclinical development.
Since its founding, the company has secured multiple rounds of funding, including an angel round in 2022 and a pre-series A round in January 2024, with investors such as Goldport Capital and Hongtao Fund Management. MagicRNA has established a 2700-square-meter facility in Shenzhen's Guangming District, which includes an R&D center and a process/quality research base. The company collaborates with institutions like Sun Yat-sen University Affiliated Hospital and West China Hospital.
Keywords: RNA therapeutics, mRNA drug development, cancer therapy, nucleic acid delivery, lipid nanoparticles, LNP delivery, gene therapy, biotechnology, oncology, drug discovery, biopharmaceuticals, infectious disease vaccines, protein replacement therapy, custom mRNA synthesis, engineered cell targeting, preclinical research, gynecological diseases, tumor vaccines, drug delivery platforms, ionizable lipids